Related Editorial
The rapidly growing cannabis industry has spawned a range of diverse companies focusing on innovative technologies for cannabis cultivation, as well as the development of cannabis-based medical therapies for an array of diseases and ailments. The market has given rise to biotech companies with exciting advances in product formulation and delivery. At the cutting-edge of innovation, PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) (PRVCF Profile) has developed an innovative cannabidiol (CBD)-based nose-to-brain delivery system for the relief of a number of medical conditions. Another company, Lexaria Bioscience Corp. (OTC: LXRP) (LXRP Profile) has developed its own proprietary system for CBD-based therapy delivery. And with a market cap of over $3.6 billion, GW Pharmaceuticals plc (NASDAQ: GWPH) is an established giant in the cannabis biotech space developing plant-derived cannabinoid therapeutics. Canadian cultivator Canopy Growth Corp. (TSE: WEED) is an example of yet another company that could benefit from its therapeutic advances as the anticipated commercial availablity of pharmaceutical-grade cannabis products is met by greater demand.
To view the full editorial, visit http://nnw.fm/3UGib